Video

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

Author(s):

Brian A. Van Tine, MD, PhD
Conference|ASCO Annual Meeting

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

At the 2020 ASCO Virtual Program, findings from a phase 1 study of ADP-A2M4 SPEAR T cells demonstrated an overall response rate (ORR) of 23.7% in 38 patients with advanced solid tumors. Moreover, an ORR of 43.8% was observed with the agent in 16 patients with synovial sarcoma.

The phase 2 SPEARHEAD-1 trial is evaluating ADP-A2M4 in patients with synovial sarcoma and myxoid/round cell liposarcoma, says Van Tine. Additionally, second-generation T cells involving CD8 are in development for use in patients with carcinoma.

Although it is still early, the durability and safety profile of this agent compared with chemotherapy suggests that ADP-A2M4 could play a role in the treatment of patients with synovial sarcoma, concludes Van Tine.

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Related Content
Jonathan W. Riess, MD, MS
July 26th 2024

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

Sara M. Tolaney, MD, MPH
July 20th 2024

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer